HomeTopics › Endometriosis

Endometriosis

GMJ News knowledge hub · last reviewed August 2026 · Georgian Medical Journal

SummaryStatisticsGlossaryGMJ newsFAQDocumentsOrganizationsResearch

Endometriosis — a chronic inflammatory disease in which tissue similar to the uterine lining grows outside the uterus — affects approximately 190 million women and girls of reproductive age globally, causing severe pelvic pain, heavy menstrual bleeding, bowel and bladder symptoms, and infertility (WHO). Despite affecting 1 in 10 women of reproductive age, the average time from symptom onset to diagnosis is 8-10 years — driven by normalisation of painful periods, inadequate clinical training and the absence of a non-invasive diagnostic test. WHO designated endometriosis as a priority chronic condition in 2023, calling for improved clinical recognition and equitable access to care.

Key messages

190 million women
Endometriosis — in which tissue similar to the uterine lining grows outside the uterus — affects approximately 190 million women and girls of reproductive age globally (1 in 10), causing severe chronic pelvic pain, dysmenorrhoea and infertility (WHO).
8-10 year diagnostic delay
Despite causing debilitating symptoms, the average time from symptom onset to diagnosis is 8-10 years — due to normalisation of painful periods, inadequate clinical training, and the absence of a reliable non-invasive diagnostic test. Many women are dismissed or misdiagnosed.
No cure
There is no cure for endometriosis. Management focuses on symptom control: hormonal therapies (combined OCP, progestins, GnRH analogues), pain management (NSAIDs, opioids for severe pain) and surgical treatment (laparoscopic excision or ablation). Symptoms often return after surgery.
Infertility cause
Endometriosis is found in 25-50% of women with infertility — caused by adhesions, tubal obstruction, inflammation and impaired follicular development. Surgical treatment improves fertility outcomes; assisted reproductive technology (IVF) is effective when surgery is insufficient.
WHO priority since 2023
WHO designated endometriosis as a chronic priority condition in 2023 — calling for improved clinical recognition, research investment and equitable access to diagnosis and care.
Menstrual health neglect
Endometriosis exists in a context of broader menstrual health neglect — painful periods normalised in many cultures, taboos preventing open discussion, and healthcare systems that dismiss women's pain. Changing this culture is central to reducing the diagnostic delay.

Key statistics

190M
women and girls with endometriosis
WHO
1 in 10
women of reproductive age
WHO
8-10yr
average diagnostic delay
WHO/research
25-50%
of infertile women have endometriosis
WHO/ESHRE
No cure
available for endometriosis
WHO
2023
year WHO designated as priority chronic condition
WHO

Endometriosis annual economic cost (USD billions) — global estimates by category

Source: Simoens et al. research estimates. Annual costs of endometriosis exceed $78 billion in the US alone.

Glossary of key terms

Endometriosis
WHO/ESHRE
A chronic inflammatory disease in which tissue morphologically and functionally similar to endometrium (the uterine lining) grows outside the uterus — on the ovaries, fallopian tubes, peritoneum, bowel, bladder or, rarely, distant sites. It responds to hormonal fluctuations of the menstrual cycle.
Dysmenorrhoea
WHO
Painful menstruation — the most common symptom of endometriosis. Primary dysmenorrhoea (no pathological cause) is distinguished from secondary dysmenorrhoea (from endometriosis, adenomyosis, fibroids). Endometriosis-associated dysmenorrhoea is often severe and not relieved by standard analgesics.
Endometrioma
ESHRE/WHO
An endometriotic cyst of the ovary — also called a "chocolate cyst" from the dark brown accumulated menstrual blood. Causes pelvic pain and reduces ovarian reserve. Surgical removal must balance endometrioma relief against ovarian damage.
Adenomyosis
WHO
A closely related condition in which endometrial glands and stroma are found within the myometrium (uterine muscle) — causing heavy, painful periods and an enlarged uterus. Often co-exists with endometriosis. Managed with hormones or hysterectomy in definitive cases.
Laparoscopy
ESHRE/ASRM
The surgical gold standard for endometriosis diagnosis and treatment — visualising and excising or ablating endometriotic lesions under magnification. Histological confirmation of endometrial tissue defines diagnosis. Repeated surgery is often needed due to disease recurrence.
GnRH analogues
WHO/ESHRE
Gonadotropin-releasing hormone analogues (leuprolide, goserelin) suppress oestrogen production, inducing a temporary menopause that suppresses endometriosis. Effective for symptom control; cannot be used indefinitely due to bone loss. Add-back hormonal therapy mitigates side effects.

Latest GMJ coverage

New Blood Test Could Cut Endometriosis Diagnosis Time From 8 Years to Months
22/06/2026
Endometriosis Affects 10% of Women Yet Faces Chronic Under-recognition, BBC Investigation Reveals
01/06/2026
Coffee and Cancer Risk: What 20 Prospective Cohorts Reveal About Protection
20/07/2026
Rare pelvic tumour safely removed through interdepartmental collaboration at Hungarian teaching hospital
11/08/2026
Spinal Nerve Network Controls Body Functions Beyond Back Pain, Research Shows
24/05/2026
Bacterial STIs Hit Decade-High in Europe as Gonorrhea and Syphilis Cases Surge
22/05/2026

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Women's healthReproductive healthChronic painOvarian cancerMaternal healthDisability

About this hub. Produced by the GMJ News Editorial Team as a public-good service. Every statistic is linked to its primary source. Documents are preserved in the GMJ Repository with full attribution. Georgian Medical Journal · Contact the editorial team
GMJ BriefsView all →